Want to see KR:005250 full AI Analyst Report?
GC Corp. (005250) Stock Price & Analysis
005250 Stock Chart & Stats
- Day’s Range
- KRW 8,950.00 - KRW 9,190.00
- 52-Week Range
- KRW 8,630.00 - KRW 18,010.00
- Previous Close
- KRW 9,120.00
- Volume
- N/A
- Average Volume (3M)
- 46.83K
- Market Cap
- KRW 418.50B
- Enterprise Value
- KRW 2.92T
- Total Cash (Recent Filing)
- KRW 107.82B
- Total Debt (Recent Filing)
- KRW 1.69T
- Price to Earnings (P/E)
- ―
- Beta
- 0.26
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 30, 2026
- Dividend Yield
- 3.28%
Bulls Say, Bears Say
Bulls Say
Diversified Dental Healthcare Portfolio
Serving dental clinics, hospitals, and laboratories across restorative, preventive, consumable, and equipment categories gives GC Corp. multiple healthcare use cases. Domestic distribution plus overseas sales channels broadens the company’s commercial reach and supports a more diversified operating base.
Improving Cash Generation
The return to positive operating cash flow and TTM free cash flow is a meaningful improvement in internal funding capacity. If maintained, stronger cash generation can help support operations and reduce reliance on external financing, although consistency remains important.
Positive EBITDA Base
Positive EBITDA indicates that the underlying operating business still generates earnings before depreciation, interest, and taxes even though net income is negative. This provides a foundation for recovery if revenue stabilizes and margin pressure eases over the coming periods.
Bears Say
Sharp TTM Revenue Decline
The sharp TTM revenue contraction, following earlier growth, shows that demand and commercial execution have been inconsistent. Sustained lower sales would weaken operating leverage, reduce the company’s ability to absorb fixed costs, and make a durable earnings recovery more difficult.
Deepening Losses And Margin Pressure
A transition from profit to increasingly deep losses, combined with gross-margin compression, signals pressure across both revenue conversion and cost absorption. Continued deterioration could consume capital, limit reinvestment, and weaken the company’s ability to compete through a downturn.
Rising Leverage And Limited Deleveraging Capacity
Leverage has nearly doubled from 2021 levels while equity has declined and returns on equity are negative. Although cash flow recently improved, its modest scale relative to debt limits financial flexibility and makes sustained deleveraging dependent on further operating recovery.
005250 FAQ
What was GC Corp.’s price range in the past 12 months?
What is GC Corp.’s market cap?
When is GC Corp.’s upcoming earnings report date?
How were GC Corp.’s earnings last quarter?
Is GC Corp. overvalued?
Does GC Corp. pay dividends?
What is GC Corp.’s EPS estimate?
How many shares outstanding does GC Corp. have?
What happened to GC Corp.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GC Corp.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GC Corp.
GC Corp., formerly known as Green Cross Holdings Corporation, is a South Korean biotechnology company. It provides a range of products including prescription drugs, vaccines, and blood plasma derivatives, and also offers pharmaceutical logistics and cell therapy services.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Yong-Jun Huh
- Employees
- 163
- Website
- www.gccorp.com
- Address
- 107, Ihyeon-Ro 30beon-Gil, Giheung-Gu, Yongin, GY, 16924, KR
GC Corp. (005250) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 13 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 1 | 0 | 11 |